Dolutegravir plus lamivudine demonstrates noninferiority to the standard-of-care three-drug regimen in treatment-naive patients with HIV without preliminary drug resistance testing. Researchers ...

HIV virus is one of the most pressing health concerns facing the modern world. Since the first reported case of HIV/AIDS in 1981, over 25 million people have died. Out of the millions of people ...

A common medication used to manage and treat HIV is becoming increasingly resistant, according to a report from the World Health Organization. Dolutegravir is an antiretroviral medication that is ...

Genotypic testing is recommended as the preferred resistance testing method to guide therapy in antiretroviral-naive and antiretroviral-experienced persons. A major limitation of clinically available ...

National HIV Testing Week 2026 is happening 9th to 15th February 2026 in the United Kingdom. However, submissions are welcome throughout the year (until the ...

Globally, around 2.6 million children and adolescents are currently living with HIV, the majority of them in Africa. These young people are much more likely to experience treatment failure than adults ...

Co announced that Medi-Cal has expanded its coverage of HIV resistance testing to include treatment naive patients as well as patients failing therapy. While genotypic resistance testing has ...

Failure to adhere to HIV treatment is costing lives The Ndovu Study is strengthening HIV treatment by redefining how treatment failure and drug resistance are detected, managed, and prevented across ...

The human immunodeficiency virus (HIV) is a pathogen so wily and protean that researchers rarely talk about curing infected patients, focusing instead on treatment and prevention. But in an ...

An international research team has identified a novel HIV antibody that targets the virus at a particularly vulnerable site ...